written on 01.06.2014
Tags:
,

GSK misses survival endpoint with Tykerb-Herceptin pairing

TAGS: ,

Glaxo announced at ASCO on Sunday that in a Phase III study<span style="font-size: 13px;">, Tykerb and Herceptin failed to improve&nbsp;</span>disease-free survival in HER2-positive early breast cancer patients over<span style="font-size: 13px;">&nbsp;Herceptin on its own.</span>

Latest Report